Resources » COVID-19 Vaccines and People with Bleeding Disorders: Safety and Accessibility
LINKS
DETAILS

Year: 2021

Language: English

This resource is also available in: Arabic French Russian Spanish

Author(s): World Federation of Hemophilia

Format: Video

COVID-19 Vaccines and People with Bleeding Disorders: Safety and Accessibility

ADDITIONAL INFORMATION

Listen to this 90-minute webinar presented on June 2, 2021 to learn about the latest WFH updates on COVID-19 vaccination for people with bleeding disorders. The webinar provided an opportunity for attendees to learn about the authorization and safety of COVID-19 vaccines, with a focus on the regulators’ perspectives from the EU and the U.S.A., and about the latest update on the CEPI, GAVI, WHO and UNICEF COVAX initiative.

The session was chaired by Glenn Pierce (WFH Vice President, Medical), and panelists included Cedric Hermans (WFH Medical board member), Manuela Mura (Scientific Officer, EMA), Peter Marks (Director, Center for Biologics Evaluation and Research, FDA), Claudia Nannei (Senior Technical Officer, WHO) and Radoslaw Kaczmarek (WFH Coagulation Product Safety, Supply, and Access Committee chair).

To download a pdf of the slides of the webinar, click the icon below.

pdf_icon

The WFH does not engage in the practice of medicine and under no circumstances recommends particular treatment for specific individuals. For diagnosis or consultation on a specific medical problem, the WFH recommends that you contact your physician or local treatment centre. Before administering any products, the WFH urges patients to check dosages with a physician or hemophilia centre staff, and to consult the pharmaceutical company’s printed instructions.

The WFH does not promote any particular pharmaceutical product and any mention of any commercial brand in this presentation is strictly for educational purposes.

RELATED RESOURCES

Documents and PDFs

WBDR 2023 Data Report

The World Bleeding Disorders Registry (WBDR) 2023 Data Report provides aggregate data on more than 14,000 people with hemophilia &

Read More >